Jacqueline S. Garcia, MD

Articles

Dr. Garcia on Efficacy of Navitoclax in Ruxolitinib-Resistant Myelofibrosis

March 28th 2020

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

Dr. Garcia on Unmet Need in Myelofibrosis

March 23rd 2020

Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.

Dr. Garcia on the Managing Thrombocytopenia With Navitoclax in Myelofibrosis

March 10th 2020

Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.

Dr. Garcia on the Tolerability of Navitoclax/Ruxolitinib in Myelofibrosis

February 26th 2020

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.

Dr. Garcia on the Role of Navitoclax in Myelofibrosis

February 21st 2020

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

Dr. Garcia on Research With the Combination of Navitoclax/Ruxolitinib in Myelofibrosis

January 18th 2020

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.